These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 1361741)
21. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Mochizuki H; Imai H; Endo K; Yokomizo K; Murata Y; Hattori N; Mizuno Y Neurosci Lett; 1994 Feb; 168(1-2):251-3. PubMed ID: 8028787 [TBL] [Abstract][Full Text] [Related]
22. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722 [TBL] [Abstract][Full Text] [Related]
23. Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey. Graham WC; Hill DR; Woodruff GN; Sambrook MA; Crossman AR Neurosci Lett; 1991 Sep; 131(1):129-34. PubMed ID: 1791971 [TBL] [Abstract][Full Text] [Related]
24. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Bergman H; Wichmann T; DeLong MR Science; 1990 Sep; 249(4975):1436-8. PubMed ID: 2402638 [TBL] [Abstract][Full Text] [Related]
25. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Bezard E; Boraud T; Bioulac B; Gross CE Eur J Neurosci; 1999 Jun; 11(6):2167-70. PubMed ID: 10336685 [TBL] [Abstract][Full Text] [Related]
26. Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas. Marzatico F; Café C; Taborelli M; Benzi G Neurochem Res; 1993 Oct; 18(10):1101-6. PubMed ID: 8255359 [TBL] [Abstract][Full Text] [Related]
27. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. Wichmann T; Bergman H; DeLong MR J Neurophysiol; 1994 Aug; 72(2):521-30. PubMed ID: 7983516 [TBL] [Abstract][Full Text] [Related]
28. COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Feng Z; Li D; Fung PC; Pei Z; Ramsden DB; Ho SL Neuroreport; 2003 Oct; 14(15):1927-9. PubMed ID: 14561922 [TBL] [Abstract][Full Text] [Related]
29. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Benazzouz A; Gross C; Féger J; Boraud T; Bioulac B Eur J Neurosci; 1993 Apr; 5(4):382-9. PubMed ID: 8261116 [TBL] [Abstract][Full Text] [Related]
30. Parkinsonism induced with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cats: behavioral, biochemical and pathological studies. Chen S; Zhou X; Xu D; Tang Q; Xu X Chin Med Sci J; 1993 Dec; 8(4):223-6. PubMed ID: 8032069 [TBL] [Abstract][Full Text] [Related]
31. The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. Bankiewicz KS; Plunkett RJ; Jacobowitz DM; Porrino L; di Porzio U; London WT; Kopin IJ; Oldfield EH J Neurosurg; 1990 Feb; 72(2):231-44. PubMed ID: 2295921 [TBL] [Abstract][Full Text] [Related]
32. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Bezard E; Imbert C; Deloire X; Bioulac B; Gross CE Brain Res; 1997 Aug; 766(1-2):107-12. PubMed ID: 9359593 [TBL] [Abstract][Full Text] [Related]
33. Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey. Tanaka J; Nakamura H; Honda S; Takada K; Kato S Acta Neuropathol; 1988; 75(4):370-6. PubMed ID: 3259063 [TBL] [Abstract][Full Text] [Related]
34. Dopamine in the extrapyramidal motor function. A study based upon the MPTP-induced primate model of parkinsonism. Chiueh CC Ann N Y Acad Sci; 1988; 515():226-38. PubMed ID: 3259118 [No Abstract] [Full Text] [Related]
35. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced hemiparkinsonism on the kinematics of a two-dimensional,multijoint arm movement in the rhesus monkey. Camarata PJ; Parker RG; Park SK; Haines SJ; Turner DA; Chae H; Ebner TJ Neuroscience; 1992; 48(3):607-19. PubMed ID: 1351272 [TBL] [Abstract][Full Text] [Related]
36. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Tsukahara T; Takeda M; Shimohama S; Ohara O; Hashimoto N Neurosurgery; 1995 Oct; 37(4):733-9; discussion 739-41. PubMed ID: 8559303 [TBL] [Abstract][Full Text] [Related]
37. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568 [TBL] [Abstract][Full Text] [Related]
38. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Waters CM; Hunt SP; Jenner P; Marsden CD Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993 [TBL] [Abstract][Full Text] [Related]
39. Mechanisms of recovery in MPTP-induced parkinsonism. Sandyk R Neuroscience; 1988 Nov; 27(2):727-9. PubMed ID: 3146035 [No Abstract] [Full Text] [Related]
40. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. Schultz W; Studer A; Jonsson G; Sundström E; Mefford I Neurosci Lett; 1985 Aug; 59(2):225-32. PubMed ID: 3877257 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]